Exact Mass: 520.2785
Exact Mass Matches: 520.2785
Found 500 metabolites which its exact mass value is equals to given mass value 520.2785
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
7beta-hydroxytaxusin
A taxane diterpenoid that is taxusin in which the hydrogen at the 7beta position is replaced by a hydroxy group.
Dolichol diphosphate
Withaperuvin D
Withaperuvin D is found in fruits. Withaperuvin D is a constituent of leaves of Physalis peruviana (Cape gooseberry) Constituent of leaves of Physalis peruviana (Cape gooseberry). Withaperuvin D is found in fruits.
rac-4-Hydroxy-4-O-(beta-D-glucuronide)-all-trans-retinyl acetate
This compound belongs to the family of Diterpene Glycosides. These are diterpenes in which an isoprene unit is glycosylated.
Nastorazepide
Caseanigrescen B
A diterpenoid of the clerodane group isolated from the leaves and flowers of Casearia nigrescens. It exhibits cytotoxicity against A2780 human ovarian cancer cell line.
Withaperuvin B
neocynapanogenin C 3-O-beta-D-oleandroside|paniculatumoside B
methyl-ent-7alpha-acetoxy-1alpha-(2-methyl-2,3-epoxybutyryloxy)-9alpha,15alpha-dihydroxykaur-16-en-19-oate|methyl-ent-7alpha-acetoxy-1alpha-<2-methyl-2,3-epoxybutyryloxy>-9alpha,15alpha-dihydroxykaur-16-en-19-oate
14-Hydroxy-3beta-(O3-methyl-beta-D-fucopyranosyloxy)-14beta-pregn-5-en-11,15,20-trion|14-hydroxy-3beta-(O3-methyl-beta-D-fucopyranosyloxy)-14beta-pregn-5-ene-11,15,20-trione
(3R,3aR,4S,11aR,13bS)-1,2,3,3a,4,5,9,11,11a,13b-decahydro-3a,11,11,13b-tetramethyl-3-{(1S)-1-[(2S)-3,6-dihydro-5-methyl-6-oxo-2H-pyran-2-yl]ethyl}-9-oxoindeo[5,4:4,5]cyclohepta[1,2-c]oxepin-4-yl acetate|heteroclitalactone G|polysperlactone A
5alpha,9alpha,10beta,13alpha-tetraacetoxy-11(15->1)abeotaxa-4(20),11-dien-15-ol|5alpha,9alpha,10beta,13alpha-tetraacetoxy-15-hydroxy-11(15->1)-abeo-taxa-4(20),11-diene|5??,9??,10??,13??-Tetraacetoxy-15-hydroxy-11(15鈥樏傗垎1)-abeo-taxa-4(20),11-diene
(3R,9S)-megastigman-5-ene-3,9-diol 9-O-alpha-L-rhamnopyranosyl-(1?2)-beta-D-glucopyranoside|pteleifoside B
(20S,22S,23S,24S,25S,26S)-12alpha,22,23,26,24,25-triepoxy-5alpha,6beta,12beta,17beta,26-pentahydroxyergosta-2-en-1-one|jaborosalactol 27
(1S*,2S*,5Z,7S*,8R*,9S*,10S*,11R*,12R*,17R*)-2,9-diacetoxy-12-butanoyloxy-8-hydroxybriara-5,13-dien-18-one|cavernulin A
Phe Gln Ala Arg
Asn Ile Phe Lys
2alpha-hydroxytaxusin
A taxane diterpenoid that is taxusin substituted by a hydroxy group at position 2alpha.
Glaucoside A
Glaucoside A is a natural product found in Vincetoxicum amplexicaule with data available.
C28H40O9_1(2H)-Naphthalenone, 2,7-bis(acetyloxy)-4-[(3E)-2,5-bis(acetyloxy)-3-methyl-3-penten-1-yl]octahydro-4a,8,8-trimethyl-3-methylene
Ala Phe Gln Arg
Ala Phe Arg Gln
Ala Gln Phe Arg
Ala Gln Arg Phe
Ala Arg Phe Gln
Ala Arg Gln Phe
Asp Lys Lys Met
Asp Lys Met Lys
Asp Met Lys Lys
Glu Phe Ile Ile
Glu Phe Ile Leu
Glu Phe Leu Ile
Glu Phe Leu Leu
Glu Ile Phe Ile
Glu Ile Phe Leu
Glu Ile Ile Phe
Glu Ile Leu Phe
Glu Leu Phe Ile
Glu Leu Phe Leu
Glu Leu Ile Phe
Glu Leu Leu Phe
Phe Ala Gln Arg
Phe Ala Arg Gln
Phe Glu Ile Ile
Phe Glu Ile Leu
Phe Glu Leu Ile
Phe Glu Leu Leu
Phe Ile Glu Ile
Phe Ile Glu Leu
Phe Ile Ile Glu
Phe Ile Lys Asn
Phe Ile Leu Glu
Phe Ile Asn Lys
Phe Ile Asn Gln
Phe Ile Gln Asn
Phe Lys Ile Asn
Phe Lys Leu Asn
Phe Lys Asn Ile
Phe Lys Asn Leu
Phe Lys Gln Val
Phe Lys Val Gln
Phe Leu Glu Ile
Phe Leu Glu Leu
Phe Leu Ile Glu
Phe Leu Lys Asn
Phe Leu Leu Glu
Phe Leu Asn Lys
Phe Leu Asn Gln
Phe Leu Gln Asn
Phe Asn Ile Lys
Phe Asn Ile Gln
Phe Asn Lys Ile
Phe Asn Lys Leu
Phe Asn Leu Lys
Phe Asn Leu Gln
Phe Asn Gln Ile
Phe Asn Gln Leu
Phe Gln Ile Asn
Phe Gln Lys Val
Phe Gln Leu Asn
Phe Gln Asn Ile
Phe Gln Asn Leu
Phe Gln Gln Val
Phe Gln Arg Ala
Phe Gln Val Lys
Phe Gln Val Gln
Phe Arg Ala Gln
Phe Arg Gln Ala
Phe Val Lys Gln
Phe Val Gln Lys
Phe Val Gln Gln
Ile Glu Phe Ile
Ile Glu Phe Leu
Ile Glu Ile Phe
Ile Glu Leu Phe
Ile Phe Glu Ile
Ile Phe Glu Leu
Ile Phe Ile Glu
Ile Phe Lys Asn
Ile Phe Leu Glu
Ile Phe Asn Lys
Ile Phe Asn Gln
Ile Phe Gln Asn
Ile Ile Glu Phe
Ile Ile Phe Glu
Ile Lys Phe Asn
Ile Lys Asn Phe
Ile Leu Glu Phe
Ile Leu Phe Glu
Ile Asn Phe Lys
Ile Asn Phe Gln
Ile Asn Lys Phe
Ile Asn Gln Phe
Ile Gln Phe Asn
Ile Gln Asn Phe
Lys Asp Lys Met
Lys Asp Met Lys
Lys Phe Ile Asn
Lys Phe Leu Asn
Lys Phe Asn Ile
Lys Phe Asn Leu
Lys Phe Gln Val
Lys Phe Val Gln
Lys Ile Phe Asn
Lys Ile Asn Phe
Lys Lys Asp Met
Lys Lys Met Asp
Lys Leu Phe Asn
Lys Leu Asn Phe
Lys Met Asp Lys
Lys Met Lys Asp
Lys Met Arg Ser
Lys Met Ser Arg
Lys Asn Phe Ile
Lys Asn Phe Leu
Lys Asn Ile Phe
Lys Asn Leu Phe
Lys Asn Pro Tyr
Lys Asn Tyr Pro
Lys Pro Asn Tyr
Lys Pro Tyr Asn
Lys Gln Phe Val
Lys Gln Val Phe
Lys Arg Met Ser
Lys Arg Ser Met
Lys Ser Met Arg
Lys Ser Arg Met
Lys Ser Thr Trp
Lys Ser Trp Thr
Lys Thr Ser Trp
Lys Thr Trp Ser
Lys Val Phe Gln
Lys Val Gln Phe
Lys Trp Ser Thr
Lys Trp Thr Ser
Lys Tyr Asn Pro
Lys Tyr Pro Asn
Leu Glu Phe Ile
Leu Glu Phe Leu
Leu Glu Ile Phe
Leu Glu Leu Phe
Leu Phe Glu Ile
Leu Phe Glu Leu
Leu Phe Ile Glu
Leu Phe Leu Glu
Leu Phe Asn Lys
Leu Phe Asn Gln
Leu Phe Gln Asn
Leu Ile Glu Phe
Leu Ile Phe Glu
Leu Lys Phe Asn
Leu Leu Glu Phe
Leu Leu Phe Glu
Leu Asn Phe Gln
Leu Asn Gln Phe
Leu Gln Phe Asn
Leu Gln Asn Phe
Met Asp Lys Lys
Met Lys Asp Lys
Met Lys Lys Asp
Met Lys Arg Ser
Met Lys Ser Arg
Met Arg Lys Ser
Met Arg Ser Lys
Met Ser Lys Arg
Met Ser Arg Lys
Asn Phe Ile Gln
Asn Phe Leu Gln
Asn Phe Gln Ile
Asn Phe Gln Leu
Asn Ile Phe Gln
Asn Ile Gln Phe
Asn Lys Leu Phe
Asn Lys Pro Tyr
Asn Lys Tyr Pro
Asn Leu Phe Lys
Asn Leu Phe Gln
Asn Leu Lys Phe
Asn Leu Gln Phe
Asn Pro Lys Tyr
Asn Pro Tyr Lys
Asn Gln Phe Ile
Asn Gln Phe Leu
Asn Gln Ile Phe
Asn Gln Leu Phe
Asn Tyr Lys Pro
Asn Tyr Pro Lys
Pro Lys Asn Tyr
Pro Lys Tyr Asn
Pro Asn Lys Tyr
Pro Asn Tyr Lys
Pro Tyr Lys Asn
Pro Tyr Asn Lys
Gln Ala Phe Arg
Gln Ala Arg Phe
Gln Phe Ala Arg
Gln Phe Ile Asn
Gln Phe Lys Val
Gln Phe Leu Asn
Gln Phe Asn Ile
Gln Phe Asn Leu
Gln Phe Gln Val
Gln Phe Arg Ala
Gln Phe Val Lys
Gln Phe Val Gln
Gln Ile Phe Asn
Gln Ile Asn Phe
Gln Lys Phe Val
Gln Lys Val Phe
Gln Leu Phe Asn
Gln Leu Asn Phe
Gln Asn Phe Ile
Gln Asn Phe Leu
Gln Asn Ile Phe
Gln Asn Leu Phe
Gln Gln Phe Val
Gln Gln Val Phe
Gln Arg Ala Phe
Gln Arg Phe Ala
Gln Val Phe Lys
Gln Val Phe Gln
Gln Val Lys Phe
Gln Val Gln Phe
Arg Ala Phe Gln
Arg Ala Gln Phe
Arg Phe Ala Gln
Arg Phe Gln Ala
Arg Lys Met Ser
Arg Lys Ser Met
Arg Met Lys Ser
Arg Met Ser Lys
Arg Gln Ala Phe
Arg Gln Phe Ala
Arg Ser Lys Met
Arg Ser Met Lys
Ser Lys Met Arg
Ser Lys Arg Met
Ser Lys Thr Trp
Ser Lys Trp Thr
Ser Met Lys Arg
Ser Met Arg Lys
Ser Arg Lys Met
Ser Arg Met Lys
Ser Thr Lys Trp
Ser Thr Trp Lys
Ser Trp Lys Thr
Ser Trp Thr Lys
Thr Lys Ser Trp
Thr Lys Trp Ser
Thr Ser Lys Trp
Thr Ser Trp Lys
Thr Trp Lys Ser
Thr Trp Ser Lys
Val Phe Lys Gln
Val Phe Gln Lys
Val Phe Gln Gln
Val Lys Phe Gln
Val Lys Gln Phe
Val Gln Phe Lys
Val Gln Phe Gln
Val Gln Lys Phe
Val Gln Gln Phe
Trp Lys Ser Thr
Trp Lys Thr Ser
Trp Ser Lys Thr
Trp Ser Thr Lys
Trp Thr Lys Ser
Trp Thr Ser Lys
Tyr Lys Asn Pro
Tyr Lys Pro Asn
Tyr Asn Lys Pro
Tyr Asn Pro Lys
Tyr Pro Lys Asn
Tyr Pro Asn Lys
26,26,26,27,27,27-hexafluoro-25-hydroxyvitamin D2 / 26,26,26,27,27,27-hexafluoro-25-hydroxyergocalciferol
Withaperuvin D
Withaperuvin
26,26,26,27,27,27-hexafluoro-25-hydroxyvitamin D2
26,26,26,27,27,27-hexafluoro-25-hydroxyvitamin D2
Gallopamil hydrochloride
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
Nastorazepide
Nastorazepide (Z-360) is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Target:CCK-2 in vitro: Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells. Check for active clinical trials or closed clinical trials using this agent. in vivo: Z-360 is a novel orally active CCK-2/gastrin receptor antagonist, significantly inhibits the growth of subcutaneous xenografts of human pancreatic tumor cells in mice, and that Z-360 combined with gemcitabine prolonged survival in a pancreatic carcinoma orthotopic xenograft mice.
1,2-Ethanediamine, N1-(3-(trimethoxysilyl)propyl)-, N-((ethenylphenyl)methyl) derivs., hydrochlorides, hydrolyzed
(4Z,7Z,9E,11E,13R,14S,16Z,19Z)-13-[(2R)-2-amino-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-14-hydroxydocosa-4,7,9,11,16,19-hexaenoic acid
Nastorazepide
7beta-Hydroxytaxa-4(20),11-diene-5alpha,9alpha,10beta,13alpha-tetrayl tetraacetate
5-(2-amino-1-hydroxyethyl)-2-[[(2R,3R,4S,5R,6R)-5-carbamoyloxy-3-(3,6-diaminohexanoylamino)-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-4,5-dihydro-1H-imidazole-4-carboxylic acid
2-Hydroxy-2alpha,5alpha,9alpha,10beta,13alpha-taxa-4(20),11-diene-5,9,10,13-tetrayl tetraacetate
S-[(3Z,6R,7S,15Z,18Z)-21-carboxy-6-hydroxyhenicosa-3,8,10,12,15,18-hexaen-7-yl]-L-cysteinylglycine
3-[(3aS,10bS)-2-[4-(3-hydroxypropoxy)phenyl]-4-oxo-5-prop-2-enyl-6,10b-dihydrooxazolo[4,5-d][2]benzazepin-3a-yl]propanoic acid tert-butyl ester
3-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
N-[[(2R,3R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide
N-[[(2S,3S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide
N-[[(2S,3R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide
N-[[(4R,5R)-8-(1-cyclohexenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(4R,5S)-8-(1-cyclohexenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(4R,5S)-8-(1-cyclohexenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(4S,5R)-8-(1-cyclohexenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(4S,5S)-8-(1-cyclohexenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
2-methoxy-N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-8-[2-(4-morpholinyl)-1-oxoethyl]-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[[(2R,3S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide
N-[[(2S,3S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide
N-[[(2R,3R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide
N-[[(2R,3S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide
N-[[(2S,3R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-(3-pyridinyl)acetamide
N-[[(4S,5S)-8-(1-cyclohexenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(4R,5R)-8-(1-cyclohexenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(4S,5R)-8-(1-cyclohexenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-[(5-phenyl-3-isoxazolyl)methyl]-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
3-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
3-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methylurea
methyl 6-{[4,6-dideoxy-3-O-(4,6-dideoxy-4-formamido-2,3-di-O-methyl-alpha-D-mannopyranosyl)-4-formamido-alpha-D-mannopyranosyl]oxy}hexanoate
(3S,6S)-3,4,5-trihydroxy-6-[[(1S,2S,10S,13R,14S,17S,18S)-17-hydroxy-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-5-yl]oxy]oxane-2-carboxylic acid
(4S,5S)-5-[(1R)-2-amino-1-hydroxyethyl]-2-[[(2R,3R,4S,5R,6R)-5-carbamoyloxy-3-[[(3S)-3,6-diaminohexanoyl]amino]-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-4,5-dihydro-1H-imidazole-4-carboxylic acid
rac-4-Hydroxy-4-O-(beta-D-glucuronide)-all-trans-retinyl acetate
(13R)-S-cysteinylglycinyl-(14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid
A docosanoid that is (14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid in which a cysteinylglycinyl group is attached at position 13R via a sulfide linkage.
16(S)-glycinylcystein-S-yl-17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoic acid
A docosanoid that is 17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoic acid in which a cysteinylglycinyl group is attached at position 16S via a sulfide linkage. An intermediate of specialized proresolving mediators
12-hydroxy-8-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one
(1s,2r,7s,8z,12r,13s,14s,16r,17r)-2,14-bis(acetyloxy)-16-hydroxy-4,9,13,17-tetramethyl-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadeca-3,8-dien-12-yl butanoate
4-{2,2,6-trimethyl-4-[(3,4,5-trihydroxy-6-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxan-2-yl)oxy]cyclohexyl}butan-2-one
8-methyl-2,16-bis(3-methylbut-2-en-1-yl)-19-(3-methylbut-3-en-1-yn-1-yl)-3,15,18-trioxahexacyclo[8.8.1.0²,⁴.0⁶,¹⁹.0¹¹,¹⁷.0¹⁴,¹⁶]nonadeca-8,11-diene-1,5,13-triol
5-isopropyl-3-[6-isopropyl-2-(2-isopropyl-4-methoxy-5-methylphenoxy)-4-methoxy-3-methylphenoxy]-2-methylcyclohexa-2,5-diene-1,4-dione
7-hydroxy-8-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one
(1s,3r,5r,6as,7r,8s,9r,10r,10ar)-1,3-bis(acetyloxy)-9,10-dihydroxy-7,8-dimethyl-7-(3-methylidenepent-4-en-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl butanoate
4-[(1s,4r,6r)-2,2,6-trimethyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}cyclohexyl]butan-2-one
6-(1-{1,3a,5,5a,6-pentahydroxy-9a,11a-dimethyl-9-oxo-2h,3h,3bh,4h,5h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-1-hydroxyethyl)-3,4-dimethyl-5,6-dihydropyran-2-one
(1s,2r,5r,10r,11r,14r,16s,17r,20s,21s,22r)-11,16,21-trihydroxy-8-isopropyl-14-methoxy-2,5-dimethyl-15,19,23-trioxahexacyclo[18.2.1.0²,¹⁰.0⁵,⁹.0¹³,²².0¹⁶,²¹]tricosa-8,12-dien-17-yl acetate
14beta-hydroxytaxusin
{"Ingredient_id": "HBIN001389","Ingredient_name": "14beta-hydroxytaxusin","Alias": "14\u03b2-hydroxytaxusin","Ingredient_formula": "C28H40O9","Ingredient_Smile": "CC1=C2C(C(C3(CCC(C(=C)C3CC(C2(C)C)C(C1OC(=O)C)O)OC(=O)C)C)OC(=O)C)OC(=O)C","Ingredient_weight": "520.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "31276;10739","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "5318353","DrugBank_id": "NA"}
2-deacetoxy-5-decinnamoyl taxinine j
{"Ingredient_id": "HBIN005491","Ingredient_name": "2-deacetoxy-5-decinnamoyl taxinine j","Alias": "NA","Ingredient_formula": "C28H40O9","Ingredient_Smile": "CC1=C2C(C(C3(C(CC(C2(C)C)CC1OC(=O)C)C(=C)C(CC3OC(=O)C)O)C)OC(=O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4703","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-deacetoxy-5-decinnamoyl taxinin j
{"Ingredient_id": "HBIN005492","Ingredient_name": "2-deacetoxy-5-decinnamoyl taxinin j","Alias": "NA","Ingredient_formula": "C28H40O9","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "26041","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5α,9α,10β,13α-tetraacetoxy-15-hydroxy-11(15→1)-abeo-taxa-4(20),11-diene
{"Ingredient_id": "HBIN011397","Ingredient_name": "5\u03b1,9\u03b1,10\u03b2,13\u03b1-tetraacetoxy-15-hydroxy-11(15\u21921)-abeo-taxa-4(20),11-diene","Alias": "NA","Ingredient_formula": "C28H40O9","Ingredient_Smile": "CC1=C2C(C(C3(CCC(C(=C)C3CC2(CC1OC(=O)C)C(C)(C)O)OC(=O)C)C)OC(=O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21012","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
7β-hydroxy-2α,5α,10β,14β-tetraacetoxytaxa-4(20),11-diene
{"Ingredient_id": "HBIN013103","Ingredient_name": "7\u03b2-hydroxy-2\u03b1,5\u03b1,10\u03b2,14\u03b2-tetraacetoxytaxa-4(20),11-diene","Alias": "NA","Ingredient_formula": "C28H40O9","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10742","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
adenanthin d
{"Ingredient_id": "HBIN014675","Ingredient_name": "adenanthin d","Alias": "NA","Ingredient_formula": "C28H40O9","Ingredient_Smile": "CC(=O)OC1CC2CC3(C1C4(C(CC3OC(=O)C)C(C(CC4OC(=O)C)O)(C)C)C)C(C2=C)OC(=O)C","Ingredient_weight": "520.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "608","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "11060386","DrugBank_id": "NA"}